FDA-cleared profile

Second Opinion® CS

Pearl Inc. · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: Acts as a CADe second reader to detect and segment caries on periapical radiographs of permanent teeth in patients aged 12 years and older; clinicians review the contours and percentage analysis in context.

Clinical role
Second-reader aid for dental health professionals that uses machine learning to detect and segment caries on periapical radiographs, presenting overlays of segmented contours with each lesion's percentage overlap with dentine and enamel.
Images and patients
X-ray/Radiography · Dental/Maxillofacial
Key limitation
Keep in mind: The system is a second reader and does not replace complete dentist review or clinical judgment; family marketing and help content do not establish exact K243234 release behavior.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Acts as a CADe second reader to detect and segment caries on periapical radiographs of permanent teeth in patients aged 12 years and older; clinicians review the contours and percentage analysis in context.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Dental/Maxillofacial Input: Periapical radiographs of permanent teeth from patients 12 years of age or older, passed through the device's API to its machine learning modules for processing.
  • Who uses it?Intended users: Dental health professionals (dentists)
  • What does the software produce?Output: The AI model outputs a visual overlay of segmented contours highlighting detected carious lesions on the periapical radiograph. It provides detection of caries and a detailed analysis of the lesion's overlap with dentin and enamel, presented as a percentage. The clinician can hover over detected caries to view a segmentation analysis in the form of percentages.
  • What is its most important limitation?Key limitation: The system is a second reader and does not replace complete dentist review or clinical judgment; family marketing and help content do not establish exact K243234 release behavior.

Clinical takeaway. Clinical role: Acts as a CADe second reader to detect and segment caries on periapical radiographs of permanent teeth in patients aged 12 years and older; clinicians review the contours and percentage analysis in context.

Evidence takeaway. Evidence from the reviewed source record: Study type: Both. Cases: 1250. Reported sensitivity: 88%. Reader-study cases: 330. Readers: 21

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Acts as a CADe second reader to detect and segment caries on periapical radiographs of permanent teeth in patients aged 12 years and older; clinicians review the contours and percentage analysis in context.
  • Exact FDA submission
  • Checked 2026-09-06

Exact clinical-use normalization from the FDA packet; this text is also the locked corrections value.

Workflow role
Second-reader aid for dental health professionals that uses machine learning to detect and segment caries on periapical radiographs, presenting overlays of segmented contours with each lesion's percentage overlap with dentine and enamel.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "It is designed to aid dental health professionals to review periapical radiographs of permanent teeth in patients 12 years of age or older as a second reader." … "Second Opinion CS detects suspected carious lesions and presents them as an overlay of segmented contours. The software highlights detected caries with an overlay and provides a detailed analysis of the lesion’s overlap with dentine and enamel, presented as a percentage.". Read from the exact FDA decision document on 2026-11-14.

Required input
Periapical radiographs of permanent teeth from patients 12 years of age or older, passed through the device's API to its machine learning modules for processing.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "It is designed to aid dental health professionals to review periapical radiographs of permanent teeth in patients 12 years of age or older as a second reader." … "The API serves as a conduit for passing imagery and metadata between the user interface and the machine learning modules.". Read from the exact FDA decision document on 2026-11-14.

Output and clinician action
The AI model outputs a visual overlay of segmented contours highlighting detected carious lesions on the periapical radiograph. It provides detection of caries and a detailed analysis of the lesion's overlap with dentin and enamel, presented as a percentage. The clinician can hover over detected caries to view a segmentation analysis in the form of percentages.
  • Exact FDA submission
  • Checked 2026-09-01

Clinical output reported in the exact-submission ACR model card.

Care setting
Adult and Pediatric
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Dental health professionals (dentists)
  • Exact FDA submission
  • Checked 2026-09-01

Intended-user text reported in the exact-submission ACR model card.

Limitations
The system is a second reader and does not replace complete dentist review or clinical judgment; family marketing and help content do not establish exact K243234 release behavior.
  • Exact FDA submission
  • Checked 2026-09-06

Exact-product limitations and clinician-review boundary from the FDA packet.

Evidence summary
Study type: Both. Cases: 1250. Reported sensitivity: 88%. Reader-study cases: 330. Readers: 21
  • Exact FDA submission
  • Checked 2026-09-01

Structured study metadata from the exact-submission ACR model card; this is not an independent evidence synthesis.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Study type: Both. Cases: 1250. Reported sensitivity: 88%. Reader-study cases: 330. Readers: 21
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Structured study metadata from the exact-submission ACR model card; this is not an independent evidence synthesis.

Reported sensitivity
88%
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Second Opinion® CS regulatory performance study summary

  • DesignStand-alone performance and reader study (ACR AI Central category)
  • PopulationAdult and Pediatric
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K243234
  • Samplen=1250
  • IndependenceIndependence not established

K243234

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
CMS states that Original Medicare does not pay for care, treatment, filling, removal or replacement of teeth or the structures directly supporting them (Social Security Act 1862(a)(12), 42 CFR 411.15(i)), except for inpatient hospital services and dental services that are integral to certain Medicare-covered medical services. This product's FDA-cleared use is analysis of dental radiographs, which falls in routine dental care, so no separate Medicare payment is expected outside those exceptions. Dental plan, CDT coding and private payer treatment of AI radiograph analysis were not reviewed, and no price or payment amount was established.
  • Service-level, not product-specific
  • Checked 2026-10-25

No product-specific code

Original Medicare dental-service exclusion applies to routine dental care; dental plan and private payer treatment not reviewed

Medicare (Original Medicare, CMS) · United States

Service-level exclusion from the CMS dental coverage page; it does not address this product by name and does not establish coverage or payment by dental plans or other payers.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Periapical radiographs of permanent teeth from patients 12 years of age or older, passed through the device's API to its machine learning modules for processing.

    Scope: Exact FDA submission. Packet wording: "It is designed to aid dental health professionals to review periapical radiographs of permanent teeth in patients 12 years of age or older as a second reader." … "The API serves as a conduit for passing imagery and metadata between the user interface and the machine learning modules.". Read from the exact FDA decision document on 2026-11-14.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-11-14 · FDA 510(k) decision material K243234: Second Opinion CS

  2. Routing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state the subject device's DICOM, PACS, RIS, or EHR interfaces. Confirm supported DICOM services and PACS, RIS, EHR, and interface versions with the vendor.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 ·

  3. AI processing

    Source context, not route validation: The exact FDA package describes Second Opinion CS as software that uses a cloud-based environment for processing, with an API passing imagery and metadata between a client user interface and machine learning modules. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "All three devices employ computer vision and machine learning to output detections, use cloud-based environments to conduct processing" … "The API serves as a conduit for passing imagery and metadata between the user interface and the machine learning modules.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA 510(k) decision material K243234: Second Opinion CS

  4. Returned objects

    Source context, not route validation: The AI model outputs a visual overlay of segmented contours highlighting detected carious lesions on the periapical radiograph. It provides detection of caries and a detailed analysis of the lesion's overlap with dentin and enamel, presented as a percentage. The clinician can hover over detected caries to view a segmentation analysis in the form of percentages.

    Scope: Exact FDA submission. Clinical output reported in the exact-submission ACR model card.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-01 · Second Opinion® CS model card (K243234)

  5. Viewer/worklist/report

    Unresolved route: The AI model outputs a visual overlay of segmented contours highlighting detected carious lesions on the periapical radiograph. It provides detection of caries and a detailed analysis of the lesion's overlap with dentin and enamel, presented as a percentage. The clinician can hover over detected caries to view a segmentation analysis in the form of percentages.

    Scope: Exact FDA submission. Clinical output reported in the exact-submission ACR model card.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-01 · Second Opinion® CS model card (K243234)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes Second Opinion CS as software that uses a cloud-based environment for processing, with an API passing imagery and metadata between a client user interface and machine learning modules. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "All three devices employ computer vision and machine learning to output detections, use cloud-based environments to conduct processing" … "The API serves as a conduit for passing imagery and metadata between the user interface and the machine learning modules.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Security
Pearl's data protection page states HIPAA-compliant logging of data access, TLS 1.2 in transit and AES-256 encryption at rest, with static code analysis and vulnerability scanning. Vendor-wide.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

Family imaging workflow

The official Second Opinion page says the family product integrates directly with the imaging system and analyzes bitewing, periapical, and panoramic images automatically.

product family · checked 2026-09-06

Exact K243234 connector versions and current commercial terms require confirmation.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243234
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • Public source
  • Exact FDA submission
  • Checked 2026-09-06

Imaging modality reported in the exact-submission ACR AI Central model card.

Anatomy
Dental/Maxillofacial
  • Public source
  • Exact FDA submission
  • Checked 2026-09-06

Anatomy normalized from explicit exact-submission ACR model-card wording.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-06-12
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
27Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored exact-submission candidate metadata had zero PubMed and ClinicalTrials.gov identifiers; this metadata screening is not a full paper or registry-record review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, vendor product page, literature index, trial registry, payer policy, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-06 - Exact FDA submission

    Official non-FDA product sources were reviewed for buyer and workflow context, but no exact-submission amount, currency, unit, term, or implementation fee was displayed. A vendor quote remains required.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Integration: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not state the subject device's DICOM, PACS, RIS, or EHR interfaces. Confirm supported DICOM services and PACS, RIS, EHR, and interface versions with the vendor.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-08-13 - Exact FDA submission

    Training, onboarding, competency, and support commitments are commercial implementation details that require current vendor documentation.

  • Monitoring: Not verified - checked 2026-08-13 - Exact FDA submission

    Local acceptance testing, production monitoring, drift review, update control, and incident escalation require a current vendor and site-specific governance plan.

11 sources - 3 history items

Source ledger

  1. K243234 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Second Opinion® CS model card (K243234)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: purpose, modality, intendedUsers, careSetting, output, reportedSensitivity, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. FDA 510(k) decision material K243234: Second Opinion CS

    U.S. Food and Drug Administration - Accessed 2026-09-06

    Scope: identity, clinical, evidence, implementation, deployment

  8. Second Opinion AI

    Pearl - Accessed 2026-09-06

    Scope: buyer_workflow, clinical, implementation

  9. What does Second Opinion detect?

    Pearl - Accessed 2026-09-06

    Scope: clinical, limitations, implementation

  10. Medicare Dental Coverage (CMS provider page)

    Centers for Medicare & Medicaid Services - Accessed 2026-10-25

    Scope: reimbursement, payerPolicy

  11. Pearl Data Protection

    Pearl - Accessed 2026-10-25

    Scope: security

Research history

  1. K243234 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K250264

SugarBug (1.x)

Bench7, Inc.

Authorized purpose: Provides automated concurrent-read detection and segmentation of caries on bitewing radiographs in patients 18 and older, adding information for the dentist while requiring complete dentist review and judgment.

Modality
X-ray/Radiography
Anatomy
Dental/Maxillofacial
Decision
2025-11-07
FDA-cleared K242437

Smile Dx®

Cube Click, Inc.

Authorized purpose: Aids dentists reviewing bitewing and periapical radiographs of permanent teeth by detecting/segmenting caries and periapical radiolucencies, identifying restorations and dental anatomy, and measuring mesial/distal bone levels; it does not replace dentist review.

Modality
X-ray/Radiography
Anatomy
Dental/Maxillofacial
Decision
2025-05-14
FDA-cleared K252086

DTX Studio Assist

Nobel Biocare C/O Medicim NV

Authorized purpose: Analyzes two-dimensional bitewing and periapical radiographs of permanent teeth in patients aged 15 and older to identify and localize caries, calculus, periapical radiolucency, root canal filling deficiency, discrepancy at an existing restoration margin, and bone loss; also supports alveolar bone-level measurement and restoration/dental-anatomy segmentation as an adjunct to dentist review.

Modality
X-ray/Radiography
Anatomy
Dental/Maxillofacial
Decision
2025-11-17
FDA-cleared K250753

VELMENI for DENTISTS (V4D)

Velmeni Inc.

Authorized purpose: Assists dentists in detecting caries, fillings/restorations, fixed prostheses, and implants on digital bitewing, periapical, and panoramic radiographs of permanent teeth in patients aged 15 years and older; final diagnoses and treatment plans remain the dentist's responsibility.

Modality
X-ray/Radiography
Anatomy
Dental/Maxillofacial
Decision
2025-09-02

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history